### - Editorial Questionnaire -

Your comments are important to us. This form provides you with the opportunity to express your opinions. Our goal is to make CNS Spectrums your source for practical and clinical neuropsychiatric information. By filling out this Questionnaire, you enable us to incorporate your views about our editorial content in future issues. Please fill out this form in its entirety. Thank you.	
Name (please print)	
Address	
City State	Zip Code
E-mail Specia	alty Date
Fax: 212-328-0600. Mail: CNS SPECTRUMS, 333	Hudson Street, 7th Floor, New York, NY 10013
1. On a scale of 1 to 5 (1=Poor, 5=Excellent), please indicate your level of interest and/or satisfaction with the editorial content in this issue.  ORIGINAL RESEARCH  1	3. Please describe your reading pattern for this issue:  ☐ Read cover to cover ☐ Skimmed table of contents ☐ Read select items of interest
<u>CASE REPORTS</u> □ 1 □ 2 □ 3 □ 4 □ 5	<ul><li>☐ Skimmed text</li><li>☐ Did not read</li></ul>
DEPARTMENTS  Trends in Psychopharmacology  1 2 3 4 5  In Session 1 2 3 4 5  Clinical Updates in Neuropsychiatry 1 2 3 4 5  Communique 1 2 3 4 5  CME 1 2 3 4 5  2. Which areas of neuropsychiatry would you like us to cover in the future?	<ul> <li>4. On a scale of 1 to 5 (1=Incomplete, 5=Comprehensive), how would you describe the depth of coverage for this issue?</li> <li>1 2 3 4 5</li> <li>5. Any other comments about CNS Spectrums' editorial content, design, or overall usefulness?</li> </ul>
	6. Please indicate your title: ☐ Neurologist ☐ Psychiatrist
Please select any of the following complimentary of CME-ACCREDITED CD-ROMs  Amyloid-Based Interventions in Alzheimer's Disease Differential Diagnosis of ADHD and Comorbid	<ul> <li>educational materials you would like to receive:</li> <li>The Role of Modified-Release Formulations in Hypnotic Therapy for Insomnia</li> <li>Pain, Stress, and Anxiety: Interrelationships and Treatment Necessities</li> </ul>
Conditions  ☐ Incorporating Pharmacogenetics into Clinical Practice: Reality of a New Tool in Psychiatry	NON-CME-ACCREDITED CD-ROMs AND HYPERCDs®  ☐ Innovative Drug Delivery Systems in the Management
☐ Management of Painful Physical Symptoms Associated with Depression and Mood Disorders	of Anxiety  ☐ Long-Term Issues in the Treatment of Sleep
☐ Recent Advances in the Treatment and Management of	Disorders  CLINICAL POCKET REFERENCE GUIDES
Excessive Daytime Sleepiness  ☐ Recognition and Treatment of Depression With or Without Comorbid Anxiety Disorders	☐ The Black Book of Psychotropic Dosing and Monitoring—11 <sup>th</sup> Edition
CME-ACCREDITED HYPERCDs®	☐ The Black Book of Alzheimer's Disease—First
☐ Cholinesterease Inhibitors Across Stages of Dementia and Cognitive Impairments in the Elderly	Edition  ☐ The Black Book of Insomnia
☐ Anxiety Disorders and Medical Illness: Risk Factors, Effectiveness Trials, and Quality of Care	☐ The Black Book of ADHD ☐ The Black Book of OCD
☐ Neuroprotection: A Therapeutic Strategy to Prevent Deterioration Associated with Schizophrenia	_ THE BILLING BOOK OF OUR

### - Editorial Questionnaire


Your comments are important to us. This form provides you with the opportunity to express your opinions. Our goal is to make CNS Spectrums your source for practical and clinical neuropsychiatric information. By filling out this Questionnaire, you enable us to incorporate your views about our editorial content in future issues. Please fill out this form in its entirety. Thank you.

Name (please print)	
Address	
City State	Zip Code
E-mail Speci	ialty Date
Fax: 212-328-0600. Mail: CNS SPECTRUMS, 333	3 Hudson Street, 7th Floor, New York, NY 10013
1. On a scale of 1 to 5 (1=Poor, 5=Excellent), please indicate your level of interest and/or satisfaction with the editorial content in this issue.  ORIGINAL RESEARCH  1 2 3 4 5  CASE REPORTS  1 2 3 4 5  DEPARTMENTS  Trends in Psychopharmacology  1 2 3 4 5  In Session  1 2 3 4 5  Clinical Updates in Neuropsychiatry  1 2 3 4 5  Communique  1 2 3 4 5  CME  1 2 3 4 5  CME  1 2 3 4 5	<ul> <li>3. Please describe your reading pattern for this issue:  □ Read cover to cover  □ Skimmed table of contents  □ Read select items of interest  □ Skimmed text  □ Did not read</li> <li>4. On a scale of 1 to 5 (1=Incomplete, 5=Comprehensive), how would you describe the depth of coverage for this issue?  □ 1 □ 2 □ 3 □ 4 □ 5</li> <li>5. Any other comments about CNS Spectrums' editorial content, design, or overall usefulness?</li> </ul>
cover in the future?	6. Please indicate your title: ☐ Neurologist ☐ Psychiatrist
Please select any of the following complimentary  CME-ACCREDITED CD-ROMs  Amyloid-Based Interventions in Alzheimer's Disease Differential Diagnosis of ADHD and Comorbid	educational materials you would like to receive:  The Role of Modified-Release Formulations in Hypnotic Therapy for Insomnia  Pain, Stress, and Anxiety: Interrelationships and Treatment Necessities
Conditions  Incorporating Pharmacogenetics into Clinical Practice: Reality of a New Tool in Psychiatry  Management of Painful Physical Symptoms Associated with Depression and Mood Disorders	NON-CME-ACCREDITED CD-ROMs AND HYPERCDs®  ☐ Innovative Drug Delivery Systems in the Management of Anxiety ☐ Long-Term Issues in the Treatment of Sleep
<ul> <li>□ Recent Advances in the Treatment and Management of Excessive Daytime Sleepiness</li> <li>□ Recognition and Treatment of Depression With or Without Comorbid Anxiety Disorders</li> </ul>	Disorders  CLINICAL POCKET REFERENCE GUIDES  The Black Book of Psychotropic Dosing and Monitoring—11 <sup>th</sup> Edition
CME-ACCREDITED HYPERCDs®  ☐ Cholinesterease Inhibitors Across Stages of Dementia and Cognitive Impairments in the Elderly  ☐ Anxiety Disorders and Medical Illness: Risk Factors, Effectiveness Trials, and Quality of Care	<ul> <li>□ The Black Book of Alzheimer's Disease—First Edition</li> <li>□ The Black Book of Insomnia</li> <li>□ The Black Book of ADHD</li> <li>□ The Black Book of OCD</li> </ul>
☐ Neuroprotection: A Therapeutic Strategy to Prevent Deterioration Associated with Schizophrenia	

CNS Spectr 13:2 161 February 2008

## ALZHEIMER'S DISEASE SUMMIT

Translating Research Advances Into Clinical Practice





### SAVE THE DATE:

Saturday, May 3, 2008 • The Park Hyatt • Washington, DC 8:00 a.m. - 7:00 p.m.

### PROGRAM CHAIRS:

JEFFREY L. CUMMINGS, MD, AND PIERRE N. TARIOT, MD

### **EDUCATIONAL SESSIONS INCLUDE:**

- Advances in Clinical Assessment
- Advances in Neuroimaging and Biomarkers
- CURRENT ALZHEIMER
  THERAPY: BEST PRACTICES
- The Future of Alzheimer Therapeutics
- Panel Discussion including Russell Katz, MD, Director of Neurology Products, FDA

For complete ADS program and registration information, please visit <a href="https://www.adsummit2008.com">www.adsummit2008.com</a>

For questions regarding the ADS, please e-mail <a href="mailto:sw@mblcommunications.com">sw@mblcommunications.com</a>

PRIMARY PSYCHIATRY

CNS SPECTRUMS


Psychiatry Weekly.

A GLOBAL COMMITMENT TO ADVANCING CNS SCIENCE, CLINICAL PRACTICE, AND EVIDENCE-BASED MEDICINE


3rd INTERNATIONAL CONGRESS ON

# W MEN'S MENTAL HEALTH MELBOURNE AUSTRALIA

17-20 March 2008







molly meet

gene



We think they'll be great together. At Vanda, we're using pharmacogenetics to match promising molecules to the right patients. So selecting the right medicine will be easier, thanks to our more personal approach. To learn more, visit www.vandapharma.com.



we take medicine personally

Printed in the USA © 2007 VANDA PHARMACEUTICALS INC. 11/07 VPN-C001

# A GOLDEN OPPORTUNITY...



## **EXCLUSIVE OFFER:**

# E-PRESCRIBING PLUS PRACTICE-BASED MEDICATION EFFECTIVENESS TRACKING

Go beyond the current benefits of e-prescribing to enhance your practice with in-depth medication effectiveness knowledge. Prescribers of psychiatric medications are cordially invited to join the powerful Akario CNS Medication Monitoring Network™ today.

#### **Benefits of Akario membership:**

- **COMPLIMENTARY** annual license to DrFirst's award-winning SureScripts GoldRx Certified Rcopia<sup>™</sup> (visit www.drfirst.com for more information) electronic prescription management system
- Plus, ADVANCED prescriber-based medication effectiveness reporting features available only to this
  exclusive network of healthcare professionals
- On-demand, patient-specific drug efficacy and tolerability reports that will enable you to evaluate and track medication effectiveness for all of your patients
- De-identified Akario network reports that allow you to compare treatment effectiveness with your patients versus that of the entire prescriber network
- In-depth data on how CNS drugs are being used in clinical practice
- Obtain real-time clinical decision support tools to avoid drug/drug interactions, drug allergies, and adverse events
- Help your patients save \$\$\$ with formulary compliance features
- Streamline your office workflow and increase productivity by:
  - Avoiding pharmacy callbacks for renewal requests
  - Renewing multiple patients' medications with one click
- Access patient medication history across healthcare providers

To see if you qualify to participate in the network and learn more about joining this groundbreaking initiative, contact us at **info@akario.com** or call **1-212-328-0800 x211** 

Free offer is only available to prescribing psychiatric and mental health practitioners with high speed Internet access (cable, DSL, or T1). Akario reserves the right to cancel memberships if the provider/member is not an active network participant.

